Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408322 | Vaccine | 2007 | 5 Pages |
Abstract
MenBvac is an OMV vaccine against systemic serogroup B Neisseria meningitidis disease. MenBvac was developed for control of a B:15:P1.7,16 subtype epidemic in Norway and administered to 180,000 subjects in 28 clinical studies. MeNZB, a daughter vaccine of MenBvac, was developed for a clonal B:4:P1.7b,4 epidemic in New Zealand and administered to 1 million people <20 years. The vaccines were similar regarding reactogenicity profile. Serious adverse events (SAEs) in general and particularly neurologic SAEs were very rare.Despite frequently reported local reactions and fever in those under 5 years, these OMV-based vaccines containing 25 μg antigen can be considered safe for use in all age groups.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
H. Nøkleby, P. Aavitsland, J. O’Hallahan, B. Feiring, S. Tilman, P. Oster,